Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance...

  • Monday, June 4, 2012, 12:38 PM ET
    Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance especially after this weekend's ASCO meeting in which both Bristol Myers (BMY flat) and Medivation (MDVN -2%) published impressive trial results for their prostate drugs. The firm loweres its 2014 and 2015 estimates for Provenge and said the drug may have trouble remaining relevant.
Track new comments on this story

This news story has 1 comment:

  •  
    Dr Cohen , where are you. Wanna see your usual +ve response and hope you have not sold out yet. :)
    4 Jun 2012, 04:37 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »